6H0E

FAB dmCBTAU-22.1 IN COMPLEX WITH TAU PEPTIDE V1088-23


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.95 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.222 
  • R-Value Observed: 0.223 

wwPDB Validation   3D Report Full Report


This is version 2.0 of the entry. See complete history


Literature

Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422containing epitope on pathological tau.

van Ameijde, J.Crespo, R.Janson, R.Juraszek, J.Siregar, B.Verveen, H.Sprengers, I.Nahar, T.Hoozemans, J.J.Steinbacher, S.Willems, R.Delbroek, L.Borgers, M.Dockx, K.Van Kolen, K.Mercken, M.Pascual, G.Koudstaal, W.Apetri, A.

(2018) Acta Neuropathol Commun 6: 59-59

  • DOI: 10.1186/s40478-018-0562-9
  • Primary Citation of Related Structures:  
    6H06, 6H0E

  • PubMed Abstract: 
  • Aggregation of tau protein and spreading of tau aggregates are pivotal pathological processes in a range of neurological disorders. Accumulating evidence suggests that immunotherapy targeting tau may be a viable therapeutic strategy. We have previously described the isolation of antibody CBTAU-22 ...

    Aggregation of tau protein and spreading of tau aggregates are pivotal pathological processes in a range of neurological disorders. Accumulating evidence suggests that immunotherapy targeting tau may be a viable therapeutic strategy. We have previously described the isolation of antibody CBTAU-22.1 from the memory B-cell repertoire of healthy human donors. CBTAU-22.1 was shown to specifically bind a disease-associated phosphorylated epitope in the C-terminus of tau (Ser 422 ) and to be able to inhibit the spreading of pathological tau aggregates from P301S spinal cord lysates in vitro, albeit with limited potency. Using a combination of rational design and random mutagenesis we have derived a variant antibody with improved affinity while maintaining the specificity of the parental antibody. This affinity improved antibody showed greatly enhanced potency in a cell-based immunodepletion assay using paired helical filaments (PHFs) derived from human Alzheimer's disease (AD) brain tissue. Moreover, the affinity improved antibody limits the in vitro aggregation propensity of full length tau species specifically phosphorylated at position 422 produced by employing a native chemical ligation approach. Together, these results indicate that in addition to being able to inhibit the spreading of pathological tau aggregates, the matured antibody can potentially also interfere with the nucleation of tau which is believed to be the first step of the pathogenic process. Finally, the functionality in a P301L transgenic mice co-injection model highlights the therapeutic potential of human antibody dmCBTAU-22.1.


    Organizational Affiliation

    Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 6, 2333, Leiden, CN, the Netherlands. AApetri@its.jnj.com.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
HUMAN FAB ANTIBODY FRAGMENT OF dmCBTAU-22.1C [auth A], E [auth C], G [auth E], A [auth H]222Homo sapiensMutation(s): 0 
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
HUMAN FAB ANTIBODY FRAGMENT OF dmCBTAU-22.1D [auth B], F [auth D], H [auth F], B [auth L]218Homo sapiensMutation(s): 0 
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetailsImage
Microtubule-associated protein tauJ [auth G], I, K [auth J], L [auth K]24Mus musculusMutation(s): 0 
Gene Names: MaptMtaptTau
UniProt & NIH Common Fund Data Resources
Find proteins for P10637 (Mus musculus)
Explore P10637 
Go to UniProtKB:  P10637
IMPC:  MGI:97180
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
PCA
Query on PCA
A [auth H], C [auth A], E [auth C], G [auth E]L-PEPTIDE LINKINGC5 H7 N O3GLN
SEP
Query on SEP
I, J [auth G], K [auth J], L [auth K]L-PEPTIDE LINKINGC3 H8 N O6 PSER
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.95 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.222 
  • R-Value Observed: 0.223 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 107.551α = 90
b = 95.502β = 112.64
c = 108.317γ = 90
Software Package:
Software NamePurpose
XDSdata reduction
XSCALEdata scaling
REFMACrefinement
MOLREPphasing

Structure Validation

View Full Validation Report




Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2018-07-25
    Type: Initial release
  • Version 2.0: 2020-03-11
    Changes: Database references, Polymer sequence